Loading...
Market
Which COVID-19 vaccine will be the most administered in the U.S. by the end of 2024?
2
Resolution / Starting Odds
Pfizer • 25%
Moderna • 25%
Novavax • 25%
Other • 25%
CDC vaccination reports and public health surveys
Story
FDA Authorizes Updated COVID Vaccines Targeting KP.2 and JN.1 Strains
Aug 30, 2024, 07:06 PM
The U.S. Food and Drug Administration (FDA) has granted emergency use authorization for updated COVID-19 vaccines from Pfizer, Moderna, and Novavax. The Pfizer and Moderna vaccines target the KP.2 variant, while the Novavax vaccine targets the JN.1 strain and is protein-based. The Novavax vaccine is authorized for individuals aged 12 and older and is expected to be available in pharmacies and healthcare facilities across the United States soon. These vaccines aim to provide better protection against currently circulating variants and are recommended for everyone in the U.S. aged six months and older. The FDA's decision comes ahead of the fall season, with a push to increase vaccination rates to prevent serious consequences of COVID-19, including hospitalization and death. Novavax's vaccine offers a third fall option for COVID-19 immunization.
View original story
Similar markets
Novavax • 25%
Moderna • 25%
Pfizer • 25%
Other • 25%
Pfizer-BioNTech • 25%
Moderna • 25%
Novavax • 25%
Other • 25%
Yes • 50%
No • 50%
Moderna • 25%
Pfizer/BioNTech • 25%
Novavax • 25%
Other • 25%
mRNA vaccines • 25%
Non-mRNA vaccines • 25%
No specific recommendation • 25%
Other vaccine types • 25%
Pfizer is perceived as most effective • 25%
Moderna is perceived as most effective • 25%
Novavax is perceived as most effective • 25%
No clear leader in perception • 25%
Pfizer has the largest market share • 25%
Moderna has the largest market share • 25%
Novavax has the largest market share • 25%
Other companies have the largest market share • 25%
Self-administration nasal spray • 25%
Traditional injection • 25%
Pharmacy-administered nasal spray • 25%
Other methods • 25%
Less than 5 million • 25%
5 million to 10 million • 25%
10 million to 15 million • 25%
More than 15 million • 25%
High (>70%) • 25%
Moderate (50-70%) • 25%
Low (30-50%) • 25%
Very Low (<30%) • 25%
Continues to endorse vaccines • 25%
Modifies recommendations • 25%
Withdraws endorsement • 25%
Takes legal action • 25%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%